MX2022009874A - Inhibidores heterociclicos de peptidil arginina desiminasa 4 (pad4). - Google Patents

Inhibidores heterociclicos de peptidil arginina desiminasa 4 (pad4).

Info

Publication number
MX2022009874A
MX2022009874A MX2022009874A MX2022009874A MX2022009874A MX 2022009874 A MX2022009874 A MX 2022009874A MX 2022009874 A MX2022009874 A MX 2022009874A MX 2022009874 A MX2022009874 A MX 2022009874A MX 2022009874 A MX2022009874 A MX 2022009874A
Authority
MX
Mexico
Prior art keywords
compounds
heterocyclic
pad4
pad4 inhibitors
inhibitors
Prior art date
Application number
MX2022009874A
Other languages
English (en)
Inventor
Deqiang Niu
Robert J Cherney
John V Duncia
Daniel S Gardner
Venkatram Reddy Paidi
Piyush Agarwal
Joseph A Tino
Srinivasan Thangathirupathy
Ramesh Kumar Sistla
Manoranjan Panda
Kumaravel Selvakumar
Xiao Zhu
Cm Vijaya Kumar
Tirupathi Rao Alajangi
Mallikarjun Reddy Sura
Krishna Mahadevu
Karuppiah Arul Mozhi Subbiah
Jalathi S Nair
Ooha Morampudi
T G Murali Dhar
Audrey Graham Ross
Paul E Gormisky
Boris M Seletsky
Alyssa H Antropow
Zhengdong Zhu
Guobin Miao
Julio Hernán Cuervo
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2022009874A publication Critical patent/MX2022009874A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a compuestos heterocíclicos sustituidos de la Fórmula (Ia), que son inhibidores de PAD4, método para preparar estos compuestos, composiciones farmacéuticas que comprenden estos compuestos y uso de estos compuestos en el tratamiento de una enfermedad o trastorno asociado con la actividad de la enzima PAD4. (ver Fórmula) (Ia) en donde (ver Fórmulas) es; (ver Fórmulas) es; y X1-X6 y R1-R8, junto con otras variables son como se definen en la presente.
MX2022009874A 2020-02-12 2021-02-11 Inhibidores heterociclicos de peptidil arginina desiminasa 4 (pad4). MX2022009874A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041006146 2020-02-12
PCT/US2021/017554 WO2021163254A1 (en) 2020-02-12 2021-02-11 Heterocyclic pad4 inhibitors

Publications (1)

Publication Number Publication Date
MX2022009874A true MX2022009874A (es) 2022-08-22

Family

ID=74856949

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009874A MX2022009874A (es) 2020-02-12 2021-02-11 Inhibidores heterociclicos de peptidil arginina desiminasa 4 (pad4).

Country Status (16)

Country Link
US (1) US20230167131A1 (es)
EP (1) EP4103559A1 (es)
JP (1) JP2023515780A (es)
KR (1) KR20220140795A (es)
CN (1) CN115348961A (es)
AR (1) AR121299A1 (es)
AU (1) AU2021219710A1 (es)
BR (1) BR112022015792A2 (es)
CA (1) CA3167753A1 (es)
CL (1) CL2022002148A1 (es)
CO (1) CO2022011388A2 (es)
IL (1) IL295506A (es)
MX (1) MX2022009874A (es)
PE (1) PE20230679A1 (es)
TW (1) TW202140477A (es)
WO (1) WO2021163254A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022021963A2 (pt) 2020-04-30 2022-12-13 Gilead Sciences Inc Inibidores macrocíclicos de peptidilarginina desiminases
EP4267562A1 (en) 2020-12-22 2023-11-01 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
US9127003B2 (en) * 2012-07-26 2015-09-08 Glaxo Group Limited 2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors
US10407407B2 (en) * 2015-05-21 2019-09-10 Glaxosmithkline Intellectual Property Development Limited Benzoimidazole derivatives as PAD4 inhibitors
AR107030A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores aza-bencimidazol de pad4
CA3007025A1 (en) * 2015-12-22 2017-06-29 Kancera Ab Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity
CN110582489B (zh) * 2017-06-30 2023-10-27 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
DK3697785T3 (da) * 2017-10-18 2023-04-03 Jubilant Epipad LLC Imidazo-pyridine forbindelser som pad-inhibitorer

Also Published As

Publication number Publication date
AR121299A1 (es) 2022-05-04
KR20220140795A (ko) 2022-10-18
JP2023515780A (ja) 2023-04-14
IL295506A (en) 2022-10-01
CO2022011388A2 (es) 2022-08-30
AU2021219710A1 (en) 2022-10-06
PE20230679A1 (es) 2023-04-21
CL2022002148A1 (es) 2023-02-24
EP4103559A1 (en) 2022-12-21
BR112022015792A2 (pt) 2022-10-11
US20230167131A1 (en) 2023-06-01
TW202140477A (zh) 2021-11-01
CA3167753A1 (en) 2021-08-19
WO2021163254A1 (en) 2021-08-19
CN115348961A (zh) 2022-11-15

Similar Documents

Publication Publication Date Title
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
PH12020500203A1 (en) Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors
WO2016118951A3 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
PL2324008T3 (pl) 3,4-diarylopirazole jako inhibitory kinazy białkowej
EP2571876A4 (en) SUBSTITUTED SEVEN-HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES
MX2022016463A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2013004491A (es) Boronatos como inhibidores de arginasa.
HK1136292A1 (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
BRPI1015568B8 (pt) derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp 17, seus usos, e composição farmacêutica
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
PH12020552135A1 (en) Kdm1a inhibitors for the treatment of disease
NZ597075A (en) 1, 2, 4-thiazolidin-3-one derivatives as AMP-activated protein kinase (AMPK) agonists for treating cancer
MX2009011276A (es) Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad.
MY160004A (en) Heterocyclically substituted aryl compounds as hif inhibitors
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
GEP20115342B (en) New diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them
MX2022009874A (es) Inhibidores heterociclicos de peptidil arginina desiminasa 4 (pad4).
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
NZ726695A (en) Gls1 inhibitors for treating disease